Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
about
Rituximab for thyroid-associated ophthalmopathyAdverse effects of biologics: a network meta-analysis and Cochrane overviewRituximab for thyroid-associated ophthalmopathyA Deeper Look into Type 1 Diabetes - Imaging Immune Responses during Onset of DiseaseImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceThe activation and inactivation of mature CD4 T cells: a case for peripheral self-nonself discriminationTargeting the trimolecular complexUnderstanding the role of B cells in atherosclerosis: potential clinical implicationsB cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody productionType 1 diabetesImmunotherapy in autoimmune type 1 diabetesPredictive models of type 1 diabetes progression: understanding T-cell cycles and their implications on autoantibody releaseDefining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus reportConcise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Genetics, pathogenesis and clinical interventions in type 1 diabetesImmune therapy in type 1 diabetes mellitusType 1 diabetes: translating mechanistic observations into effective clinical outcomesRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialHistone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic childrenIn vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetesGenome-wide association analysis of autoantibody positivity in type 1 diabetes cases.Standards of medical care in diabetes--2013Type 1 diabetes mellitus.B cells and atherosclerosis.Investigating the role of T-cell avidity and killing efficacy in relation to type 1 diabetes prediction.Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet dataCorrelation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.B cell deficient mice are protected from biliary obstruction in the rotavirus-induced mouse model of biliary atresia.Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.Restoring the balance: immunotherapeutic combinations for autoimmune disease2011 Update: antigen-specific therapy in type 1 diabetesTargeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with RituximabRationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.Prevention trumps treatment of antibody-mediated transplant rejectionImmunotherapy of type 1 diabetes: where are we and where should we be going?Immunoglobulin M gene association with autoantibody reactivity and type 1 diabetes.Germinal centre frequency is decreased in pancreatic lymph nodes from individuals with recent-onset type 1 diabetes.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects
P2860
Q24202845-A91CFB3F-8E31-43E4-B7F1-6DC6751EFDDAQ24234197-4C56A76A-F51C-4A15-B7F9-E37AFAD99A5FQ24235160-4AEDAAF4-0926-49E0-9848-1446329E54B4Q26738317-D80B826F-5589-4FA9-8095-AE79A68EB350Q26850621-963D6699-A9F8-4C9D-B7DC-6A8168DC6E04Q26859223-82152078-A195-467B-A714-9211221A8F02Q26864985-49ABFBB6-79A6-496C-96D5-33E712A463D0Q26991813-2123ABE4-9642-48CB-A66B-F0F18CA8B454Q26996644-A12F843B-769D-4222-8084-F17E10812432Q27000491-6F5C72E3-DBBC-4EC5-8C9C-5A7E4E76FCFAQ27025619-12AFED73-2763-4C43-99F5-D7CDD629CA40Q27312237-595B83E4-5795-41CD-B9FB-F6365206AC21Q27687598-AD989EB8-2261-47AF-AC10-2CC4EB915091Q28071490-8A2BD7D9-5F3B-4B5D-9F51-49F707E047DCQ28081034-B1ED2207-C275-4C65-A5D0-AE4741C8A91AQ28281029-66C5689C-AA90-41D6-968E-9108605AB9B1Q28282846-77129A36-F0D5-4BF6-B707-5B6B42AFA445Q28287737-2DAF0476-E06D-4066-AEE1-B7DD7206C9FFQ28554636-71CEF597-9EDB-4FD7-934F-342A6040A8F5Q28575131-915E55CB-D680-4A6F-8C1F-5AFD01664B46Q28748969-A452FB3A-6DD7-4707-B8B9-B5BFE1A12DA3Q29417005-185B2EF5-7657-4014-8BE4-999A84496539Q29620309-6F38B492-A021-4F6D-AD06-BAF25B41092FQ30235021-7864C83E-B139-420C-AA3D-5145AB94BB42Q30252928-D8ECAA9A-D962-4C4B-BEAA-4D50C314E7F8Q30500186-01AE2160-C773-4608-9540-AFFC409B75FFQ30521476-733DCA80-8F9E-433C-A40F-982A764864C8Q31099230-1F9B43B9-2B60-449A-9DF9-33568795BCDFQ31133805-F07E3DB8-5210-4B9A-A0EC-C699A72DF9BFQ33413423-ED7473E4-8471-49DC-925B-16FFBF42FEEAQ33555986-094AC1AC-E073-4637-9C0F-10167025BAFAQ33593629-FA8E0F78-5CE5-41C6-89CE-23C03855808DQ33741009-8F39E9B3-00B1-4A6E-B5F2-C2FF85F61FF3Q33744839-1CF3EF14-2432-4BB4-86B2-F3FDE293B0A5Q33750667-119AE886-9A03-4BF9-8F16-C6E1C12E01A8Q33755462-BAA3FD85-9189-4D8D-95DA-017438E18337Q33815506-FEFF97D5-915D-4E3C-9D02-BE47770ACB42Q33841459-218B456E-7A9B-4611-A66E-40FCD45C3670Q33843700-CA1CC61D-F121-4CA4-9F47-7CF6A01886D0Q33905411-68620880-F419-4122-AF42-CB6B4BADE137
P2860
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
description
article
@en
im November 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2009
@uk
name
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@en
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@nl
type
label
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@en
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@nl
prefLabel
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@en
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@nl
P2093
P356
P1476
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
@en
P2093
Antoinette M Moran
Carla J Greenbaum
Darrell M Wilson
Desmond A Schatz
Diane Wherrett
Dorothy J Becker
Heidi Krause-Steinrauf
Henry Rodriguez
Jay S Skyler
Jennifer B Marks
P304
P356
10.1056/NEJMOA0904452
P407
P577
2009-11-01T00:00:00Z